CagriSema is an investigational once-weekly injectable weight-loss medication from Novo Nordisk that combines two active peptides, semaglutide and cagrilintide, in a single dose
A research guide to the component mechanisms and the co-administration rationale
This includes genes involved in collagen synthesis, antioxidant defense, DNA repair, stem cell function, and inflammation
doi: 10.4291/wjgp.v5.i4.400 12 AlvesF.KalinowskiP.AytonS
All analyses were approved by the institutional review board of the University Clinic of Erlangen (#4564) and the West China Hospital of the Sichuan University (ChiCTR1900022605)
No matter the treatment plan or your goals, our team is with you every step of the way to help you achieve optimal results